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Abstract
The Epstein-Barr virus (EBV) nuclear antigen leader protein (EBNA-LP) is the first viral
latency-associated protein produced after EBV infection of resting B cells. Its role in B cell
transformation is poorly defined, but it has been reported to enhance gene activation by the
EBV protein EBNA2 in vitro. We generated EBNA-LP knockout (LPKO) EBVs containing a
STOP codon within each repeat unit of internal repeat 1 (IR1). EBNA-LP-mutant EBVs
established lymphoblastoid cell lines (LCLs) from adult B cells at reduced efficiency, but
not from umbilical cord B cells, which died approximately two weeks after infection. Adult B
cells only established EBNA-LP-null LCLs with a memory (CD27+) phenotype. Quantitative
PCR analysis of virus gene expression after infection identified both an altered ratio of the
EBNA genes, and a dramatic reduction in transcript levels of both EBNA2-regulated virus
genes (LMP1 and LMP2) and the EBNA2-independent EBER genes in the first 2 weeks. By
30 days post infection, LPKO transcription was the same as wild-type EBV. In contrast,
EBNA2-regulated cellular genes were induced efficiently by LPKO viruses. Chromatin
immunoprecipitation revealed that EBNA2 and the host transcription factors EBF1 and
RBPJ were delayed in their recruitment to all viral latency promoters tested, whereas these
same factors were recruited efficiently to several host genes, which exhibited increased
EBNA2 recruitment. We conclude that EBNA-LP does not simply co-operate with EBNA2 in
activating gene transcription, but rather facilitates the recruitment of several transcription
factors to the viral genome, to enable transcription of virus latency genes. Additionally, our
findings suggest that EBNA-LP is essential for the survival of EBV-infected naïve B cells.
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Author summary
Epstein-Barr virus (EBV) infects almost everyone. Once infected, people harbor the virus
for life, shedding it in saliva. Infection of children is asymptomatic, but a first infection
during adolescence or adulthood can cause glandular fever (infectious mononucleosis).
EBV is also implicated in several different cancers. EBV infection of B cells (antibody-pro-
ducing immune cells) can drive them to replicate almost indefinitely (‘transformation’),
generating cell lines. We have investigated the role of an EBV protein (EBNA-LP) which
is thought to support gene activation by the essential virus protein EBNA2. We have made
an EBV in which the EBNA-LP gene has been disrupted. This virus (LPKO) shows several
properties. 1. It is reduced in its ability to transform B cells; 2. ‘Naïve’ B cells (those whose
antibodies have not adapted to fight infections) die two weeks after LPKO infection; 3.
Some virus genes fail to turn on immediately after LPKO infection. 4. Binding of EBNA2
and various cellular factors to these genes is delayed. 5. EBNA-LP does not affect EBNA2-
targeted cellular genes in the same way. This shows that EBNA-LP is more important in
naïve B cells, and that it helps to turn on virus genes, but not cell genes.
Introduction
Epstein-Barr virus is a ubiquitous human herpesvirus that asymptomatically infects the vast
majority of the human population, particularly in the developing world, where primary infec-
tion typically occurs during the first few years of life, leading to lifelong EBV latency. Where
primary infection is delayed into adolescence or adulthood, it can result in the temporarily
debilitating but relatively benign condition, infectious mononucleosis. The major disease bur-
den caused by EBV is the range of malignancies with which it has been associated. In particular
EBV contributes to high levels of Burkitt lymphoma in sub-Saharan Africa and of nasopharyn-
geal carcinoma in southeast Asia, as well as around a third of Hodgkin lymphoma cases,
approximately one in ten gastric cancers, a range of B cell lymphomas in the immunosup-
pressed and more rarely with T and NK cell malignancies. Taken together EBV is implicated
in around 1-1.5% of worldwide cancer incidence [1].
These diverse malignancies likely arise due to defects at different stages of the virus life
cycle, or perhaps infection of cell types not involved in the virus’s natural life cycle [2]. The
core of the EBV lifecycle occurs with the B cell compartment. EBV infection activates B cells,
transforming them into proliferating lymphoblasts. In vitro these continue to proliferate into
lymphoblastoid cell lines (LCLs) whereas in vivo they can differentiate – probably via a germi-
nal center – into resting memory B cells where the virus is quiescent, producing RNAs but no
viral proteins [3,4]. LCLs express the ‘growth’ program of EBV genes (latency state III), com-
prising six EBV nuclear antigens (EBNAs), the latency membrane proteins (LMP1, LMP2A
and LMP2B) and a number of EBV encoded RNAs, including the abundant nuclear RNAs
EBER1 and EBER2.
The latency III transcriptional program takes over 2 weeks to reach this state [5]. The first
EBV proteins detectable after primary infection are EBNA2 and the EBNA leader protein
(EBNA-LP) [6,7]. Shortly after this the EBNA3 proteins also become detectable [6], and the
EBNAs rapidly reach the levels found in LCLs. In contrast, the LMP proteins take up to three
weeks to reach LCL-like levels [5] [8]. EBNA transcription is initiated at multiple copies of
Wp, the promoter in the major internal repeat (IR1) of EBV. Soon after infection, the burden
of EBNA transcription shifts to Cp, a promoter upstream of IR1. Transcripts from both Cp
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and Wp are alternatively spliced, and translated in both cap- and IRES-dependent manners to
produce the six EBNAs.
The functions of most of the EBNAs are reasonably well understood: EBNA1 is important
for the replication and segregation of the viral genome during the cell cycle, by binding to
oriP. The EBNA1/oriP complex is also important in the switch from Wp to Cp [9]. EBNA2 is
essential for the initial transformation of B cells, rapidly activating both host and viral genes
through its recruitment to promoters or enhancers alongside cellular transcription factors
such as Pu.1 [10], RBPJ (also called CBF1) [11],[12], IRF4 and EBF1 [13,14]. The EBNA3 pro-
teins are slow-acting transcriptional repressors that are important for suppressing senescence
and apoptosis around 3 weeks after infection [15,16]. Notably, the EBNA3s and EBNA2 appear
to have a close relationship with each other, co-regulating genes and being bound at many of
the same chromosomal locations [13,17–19].
In contrast to the other EBNAs, the role played by EBNA-LP in B cell transformation is not
clear. Through initiation at different Wp promoters and exon skipping in Cp transcripts, the
EBNA-LP protein comprises a variable copy number of a 66 amino-acid N terminal repeat
domain (encoded by exons W1 and W2 within IR1) and a C terminal domain encoded by
exons Y1 and Y2. In LCLs, EBNA-LP mainly localizes to PML nuclear bodies [20] – nuclear
foci implicated in repression of virus infection, also called nuclear domain 10 (ND10) [21] –
although it takes several days after infection to accumulate there [22]. Functionally, EBNA-LP
has been shown to enhance the activation of host and viral genes by EBNA2 after transfection,
although not all studies agree on which genes are affected [7,23–27].
The complex repetitive nature of the EBNA-LP gene makes its analysis in the viral context chal-
lenging. Previous genetic analyses of EBNA-LP have been restricted to mutation of the C-terminal
Y exons [28,29]. These Y domain knockout viruses establish LCLs at a much reduced efficiency,
and then only when the early outgrowth of the cell lines was supported by growth on irradiated
fibroblast feeder cells. Deleting IR1 repeat units below five progressively reduced transformation
efficiency [30], but as well as reducing EBNA-LP size, this reduced transcript dosage of EBNA-LP
and EBNA2 – and probably of the recently identified stable intronic sequence RNAs (sisRNA1
and sisRNA2) [31] – due to the reduced Wp number producing fewer EBNA transcripts.
These prior studies of EBNA-LP function have been conducted in the context of transfect-
ing isolated genes, and/or in the presence of the truncated EBNA-LP protein produced by the
P3HR1 virus, and not in the context of virus infection. Therefore, the aim of this project was to
produce a complete EBNA-LP knockout virus, and use it to establish the importance of (and a
role for) EBNA-LP in the transformation of B cells. While our first EBNA-LP knockout was
additionally defective due to unintended mutations in the introns between the EBNA-LP
exons in IR1, a second, cleaner knockout showed that EBNA-LP is important but dispensable
for the transformation of adult memory B cells, but is essential for the transformation of naïve
B cells. Furthermore, both knockouts demonstrated that EBNA-LP is crucial for establishing
and stabilizing the viral transcription program after infection, and for facilitating the recruit-
ment of EBNA2 and the host protein EBF1 to the incoming virus genome. However, EBNA-LP
did not enhance the induction of host genes by EBNA2 during infection, which had been
expected based on prior understanding of its function.
Results
Generation and validation of EBNA2- and EBNA-LP-deficient EBVs
reveals a role for IR1 intronic sequences in transformation
EBNA-LP is transcribed across IR1 (Fig 1A). Each repeat unit contains the Wp promoter from
which its transcription can initiate, and repeat units can be skipped by splicing (Fig 1B).
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Therefore the only approach to reliably knockout EBNA-LP is to introduce a nonsense muta-
tion into the EBNA-LP coding region in each of the IR1 repeat units of EBV. To do this, we
generated an array of 6.6 IR1 repeat units (typical for circulating viruses [32], and matching
the size in the parental B95-8 BAC, WTHB9) containing a STOP codon mutation (and restric-
tion site for screening – Fig 1C).
In order to separate the role of EBNA2 from that of EBNA-LP, an EBNA2 knockout
(E2KO) EBV – and its revertant, E2rev – were also generated. E2KO retains the entire Y3 exon
and its 3’ splice site. This allows qPCR detection of Y2-YH EBNA2 transcripts in the E2KO,
despite being deleted for the rest of the EBNA2 ORF (Fig 1D). In order to facilitate comparison
with the previous genetic studies of EBNA-LP function in a P3HR1 strain backbone [28,29],
we also generated a pair of recombinant viruses (designated YKO) that deleted a genome
region from within exon Y1 to within exon Y2. This deleted the Y exon encoded region of
Fig 1. Construction of EBNA-LP knockouts and their revertants. A. Schematic representation of the EBV genome showing the latency genes and internal repeat 1
(IR1) across which the repetitive domain of EBNA-LP is transcribed. Region from the LMP genes to EBNA2 (dotted line) crosses the termini of the linear genome and
is shown in B. Promoters Cp and Wp are indicated by bent arrows; exons are green (right facing) or purple (left facing) arrows, with intact ORFs indicated in other
colours. Names of EBNA exons are shown below the relevant arrow. The splicing of latency genes is indicated above (plus strand transcripts) or below (minus strand
transcripts) the exons. Two examples of the alternatively spliced EBNA transcripts are shown, indicating variable numbers of W exon pairs in EBNA-LP, variable use of
Cp and Wp promoters, and differential splicing producing either EBNA2 or other downstream EBNAs. Variations in the W1 splice acceptor from C2 or W0 (red
asterisks) define whether a transcript encodes EBNA2 or EBNA-LP. C-E Mutations introduced into recombinant viruses. Parental B95-8 sequence is shown above the
introduced mutation used to generate: C. EBNA-LP knockout; D. EBNA2 knockout; E. EBNA-LP Y exon knockout. F. Flow chart showing set of recombineering steps
used to generate the recombinant EBVs constructed for this study. Note that viruses whose IR1 is mutated are made via an intermediate (WKO) in which IR1 has been
entirely deleted. Coloured names indicate recombinant BACs that were used to generate the viruses used in experiments–Green names are wild-type in sequence and
phenotype; Red names are mutants; LPrevi is shown in purple, as it contains a point change compared to wild-type that was intended to be phenotypically neutral.
Alternative lab names are included for reference.
https://doi.org/10.1371/journal.ppat.1006890.g001
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EBNA-LP, but retained exon Y1 splice acceptor and exon Y2 splice donor (Fig 1E). A revertant
(Yrev) was generated for one of these knockouts.
Two distinct approaches were used to generate the IR1 repeat arrays used to generate
LPKO viruses. The first used type IIS restriction enzymes, a method that necessitated the inclu-
sion of a point mutation in the small intron between exons W1 and W2 (S1 Fig). Duplicate
knockouts were made by this method, and a revertant was made of each (Fig 1F). Because of
the intronic mutation, these viruses were designated LPKOi and LPrevi respectively [the ‘i’
indicating intronic mutation]. The recombinant viruses were checked for unwanted deletions
by restriction digest and pulsed field gel electrophoresis (S2 Fig). It was subsequently discov-
ered that the IR1 repeat unit used to clone LPKOi and LPrevi viruses contained three minority
variants (in the BWRF1 putative open reading frame), normally found in only one IR1 repeat
unit of B95-8 [33]. Thus LPKOi and LPrevi have four nucleotide changes to the intronic
sequences in IR1, relative to the B95-8 consensus sequence.
Recombinant virus genomes were transfected into 293 cells and clones selected from which
virus could be produced. EBV-BAC DNA was rescued into bacteria from these producer cell
lines to ensure that the virus genome was unchanged. The recombinant viruses were initially
assessed in BL31 cells, which can be used to assess EBVs regardless of whether they are capable
of transforming primary B cells into LCLs [34,35]. The mutations did not alter the splicing of
EBNA transcripts initiated at either Cp or Wp (S3A Fig), other than the expected shortening
of transcripts in YKO cell lines caused by the deletion in the Y1 and Y2 exons. Nor did they
reduce the levels of any latency proteins other than those that had been mutated (S3B Fig, S4
Fig). EBNA-LP protein levels were higher in E2KO-infected BL31, while LPrevi viruses tended
to have both larger and more abundant EBNA-LP isoforms. In contrast EBNA-LP levels were
very low in YKO-infected cells. These changes in EBNA-LP levels were also seen by immuno-
fluorescence in newly infected primary B cells, which also showed that most of the truncated
EBNA-LP in YKO cells was restricted to a nuclear subregion, possibly the nucleolus (S5 Fig).
We have recently shown that the B95-8 strain of EBV, and the WTHB9 BAC contain a stop
codon at the end of exon W1 in one of its IR1 repeat units, and that this results in the produc-
tion of less EBNA-LP [33]. This explains the apparent increase in EBNA-LP size and quantity
in LPrevi, and may contribute to the reduced protein level in YKO, but does not explain the
substantially increased EBNA-LP production by E2KO.
Resting adult B cells were infected with the recombinant viruses at equal titres to assess the
abilities of viruses to transform B cells into LCLs. Three days post infection, E2KO-infected B
cells were indistinguishable from uninfected cells, whereas all other viruses induced enlarge-
ment and aggregation of the cells (S6 Fig). After that time, LPKOi showed very poor replica-
tion efficiency and usually failed to establish LCLs, whereas YKO consistently established
LCLs. In the case where an LPKOi LCL was established on feeder cells and maintained the
LPKOi genome (identified by episome rescue), EBNA-LP originating from an alternative EBV
strain was detected (S7 Fig), suggesting that LPKOi could be complemented by the virus strain
endogenous to the B cell donor, but could not establish an LCL alone. Analysis of cell prolifera-
tion in the first week post infection confirmed a previous report that proliferation of EBV-
infected cells begins over three days post infection [36], and showed that LPKOi was very inef-
ficient at driving cellular proliferation, while YKO was better (S8 Fig). However, LPrevi was
also poor at driving proliferation, being similar to YKO rather than being like WTHB9 and the
other revertants (S8 Fig).
Since two independent pairs of LPKOi and LPrevi showed the same phenotype – LPKOi was
substantially more impaired than YKO (which itself produced so little truncated EBNA-LP pro-
tein, that it may be functionally a knockout) and LPrevi exhibited defective transformation of B
cells – we suggest that at least one of the intronic mutations in these viruses (ie the designed
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point mutation in the short intron, and/or the unintended minor variants in the BWRF1 ORF
[33]) causes this defect. In order to assess the function of EBNA-LP without these confounding
intronic IR1 mutations, a second method – Gibson assembly [37] – was used to produce a new
recombinants of IR1, assembling repeat units that matched the B95-8 consensus between the
flanking sequences from the B95-8 BAC (S9A Fig). One repeat array was assembled to produce
a new wild-type IR1, and another containing the EBNA-LP mutation shown in Fig 1A. Thus
the whole IR1 sequence (other than the defined EBNA-LP mutation) in these IR1 constructs
matches the published B95-8 sequence (NC_007605). These repeat arrays were recombined
into the IR1-knock-out to make two independent LPKOw BACs (where ‘w’ indicates wild-type
IR1 backbone) and a repaired wild-type EBV with no IR1 heterogeneity (WTw) (Fig 1F). These
were validated by pulsed field gel electrophoresis (S9B Fig) and used to generate virus-produc-
ing cell lines. Thus these new viruses represent a clean EBNA-LP knockout (LPKOw), and a
wild-type virus (WTw) with a fully intact set of EBNA-LP exons.
LCLs can be established using LPKOw and its wild-type counterpart
LPKOw and WTw were used to infect CD19-purified adult B cells alongside E2KO and YKO.
Their proliferation after infection was assessed by dilution of the cell trace violet stain applied
to the B cells prior to infection. As previously reported [36] EBV-infected cells did not divide
until after day 3 post infection (S10 Fig). At 8 days post infection LPKOw is superior to LPKOi
in driving infected B cells to undergo proliferation, approaching the level seen for YKO, sug-
gesting that many of the important functions lost in LPKOw are also missing in the YKO.
WTw matches (and perhaps exceeds) the transforming capability of the parental wild-type
BAC and revertants (Fig 2A). LPKOw and WTw were both able to establish LCLs. Latency pro-
tein levels were largely similar between the LCLs, with LPKOw LCLs clearly lacking EBNA-LP
(Fig 2B), and WTw showing an elevated level of EBNA-LP relative to the parental wild-type
(WTHB9), due to the absence of a W1 mutation in a single IR1 repeat unit (Fig 2B and [33]).
LCLs could be reliably established from YKO, LPKOw and LPrevi (with weekly media
changes that did not disturb cell clusters): robust expansion of B cell cultures infected by these
mutant viruses was usually obvious from around 2 weeks after infection. To quantify this,
5x105 adult B cells from peripheral blood of two donors were infected at an MOI of 1 (based
on Raji green unit titre), and twice weekly the clumping cells were dispersed and cells counted
(Fig 2C). While donors differed in how rapidly LCLs were established, EBNA-LP-deficient B
cells grew out more slowly than the wild-type viruses. There was little or no difference between
LPKOw and YKO outgrowth, nor between WTw and WTHB9 or Yrev (Fig 2C), even though
WTw expressed considerably more EBNA-LP (Fig 2D). LPrevi outgrowth was more delayed
than in previous experiments, and proliferated poorly when at low density, suggesting that its
outgrowth was negatively affected by the repeated disruption of cells for counting. Western
blotting confirmed the lack of EBNA-LP in LPKOw, the very low level of truncated EBNA-LP
produced by YKO and the wider range of EBNA-LP isoforms produced by LPrevi (Fig 2D).
EBNA-LP mutant EBVs are defective in transforming cord blood B
lymphocytes
In addition to these infections of adult B cells, we also infected mononuclear cells from umbili-
cal cord blood to try to establish LCLs. However, we were reproducibly unable to establish
cord blood LCLs with the LPKOw virus, regardless of whether CD19-purified B cells or total
PBMCs were used, or if outgrowth was supported with irradiated MRC5 feeder cells. WTHB9,
WTw, and importantly, LPrevi – the severity of its transformation defect being similar to
LPKOw – were all consistently able to establish LCLs from cord blood. To investigate what was
Genetic analysis of EBNA-LP function
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Fig 2. An EBNA-LP knockout EBV, LPKOw is transformation competent. A. Cell proliferation of primary B cells 8 days post-infection, assessed by dilution
of cell trace violet. The shown populations are gated for live single cells and CD20 positivity. B. Western blotting of viral proteins in LCLs established with
LPKOw and WTw viruses. C. Cell counts to quantify outgrowth of 5x105 adult B cells from two donors infected with various recombinant viruses (see key). Cells
were disrupted and counted twice weekly. Cell count data are in S1 Data. D. Western blot showing EBNA-LP expression in LCLs established from the infections
counted in C, with EBNA3C used as a loading control.
https://doi.org/10.1371/journal.ppat.1006890.g002
Genetic analysis of EBNA-LP function
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006890 February 20, 2018 7 / 34
happening to the infected cells, we compared the cell cycle profile of B cells from umbilical
cord blood with adult blood after LPKOw and WTw infection (Fig 3A). While more cell death
is evident in LPKOw than WTw-infected cells for both adult and cord blood (indicated by the
subG1 population of cells) the difference is much more stark in cord cells, with both more
dead cells and – by day 11 – far fewer cells in S or G2 phases of the cell cycle. By approximately
14 days post infection (precise timing varied with different donors), there were not enough
live LPKOw-infected cord cells to analyse the cell cycle, and any remaining clumps of cells dis-
integrated and never recovered.
Fig 3. EBNA-LP mutants are defective at transforming B cells from cord blood. A. Cell cycle profiles of CD19+sorted adult and cord B
cells infected with WTw or LPKOw viruses. Plots show the DNA quantity per cell (from DAPI staining). Quantities associated with different
cell cycle phases are indicated. B. Transformation efficiencies for each infection were calculated from two-fold dilutions of infected cells (see
Methods). These efficiencies were averaged for each virus group in each cell type across 3 (maternal–orange bar) or 5 (cord–blue bar)
infections per virus. Black dotted lines indicate the sensitivity of the analysis for each virus–ie the calculated efficiency if only one well across
all of the infections was positive. C. Outgrowth of LCLs from cord blood measured by counting the number of activated (ie large) cells. Cell
count data are in S2 Data.
https://doi.org/10.1371/journal.ppat.1006890.g003
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In order to quantify this transformation defect, we conducted a dilution cloning experiment
comparing transformation of blood from the umbilical cord with blood taken at the same time
from the baby’s mother. This was performed for three donor pairs, and LPKOw and YKO viruses
consistently failed to transform cord blood into LCLs, despite successfully transforming the ma-
ternal cells into LCLs (Fig 3B). In contrast, both the wild type viruses (WTw, Yrev and WTHB9)
and LPrevi showed no difference in transformation efficiency between cord and maternal lym-
phocytes. We then used cell counting to further characterize the outgrowth efficiency of the
viruses in cord blood. Counting only cells that were larger than resting B cells (ie the activated,
LCL-like cells) it was clear that while wild-type and LPrevi-infected cell numbers increased con-
sistently after infection, YKO and LPKOw infected cell numbers fell from around 10 days post
infection (Fig 3C), consistent with the death of EBNA-LP-deficient cells at this time. In addition,
WTw-infected cells expanded faster than the other wild-types (which make less EBNA-LP: Fig 2
and [33]). This faster expansion was also seen in the transformation assay. Since EBNA-LP-
knockout EBV fails to transform cord blood cells, whereas the similarly deficient LPrevi can, this
failure does not represent a technical inability to establish cord LCLs with defective viruses in
general. Therefore, we can conclude that EBV-transformed cord blood cells require EBNA-LP
for their survival at a specific phase approximately 10–14 days post infection.
EBNA-LP-deficient EBV is more defective in transforming adult naïve B
cells than memory B cells
One key difference between adult B cells and cord-derived B cells is that the former are a het-
erogeneous mixture of different B cell subsets, whereas cord blood contains exclusively naïve B
cells, as in utero the baby’s immune system has not yet encountered any pathogens. We there-
fore tested whether different adult B cell subsets differed in their susceptibility to transforma-
tion by LPKOw. B cells were sorted into subsets according to their CD27 and IgD status (S11
Fig): CD27-positive B cells are either class-switched (IgD-) or non-switched (IgD+) memory B
cells; naïve B cells are CD27-/IgD+; and the double-negative population (CD27-/IgD-) is unde-
fined, but is reported to have memory B cell-like properties [38]. All populations were isolated
at 97–100% purity (S12 Fig). These populations (from six different donors) were infected with
LPKOw and WTw EBV, and cultured to establish LCLs. Both WTw and LPKOw LCLs were
established from the two memory B cell subsets of all donors tested, and (despite small cell
numbers) the double negative population also established LPKOw LCLs. Despite using the
same MOIs and culture conditions, adult naïve B cells established WTw LCLs more slowly
than memory B cells. Nine attempts (from six donors) were made to transform naïve B cells
with LPKOw and only one (LC2) did so, and during outgrowth this culture exhibited a sub-
stantial loss of cells two weeks post infection.
To better quantify the outgrowth, two additional donors were sorted into subsets and
infected with different virus mutants at an MOI of approximately 1 (although cell numbers
varied according to the yield of cells of each population–S1 Data) and counted twice weekly
(Fig 4A). For these two donors, LPKOw and YKO were able to establish LCLs from the sorted
naïve B cells, although they took considerably longer to grow out than from memory B cells,
and exhibited a fall in the number of infected cells in weeks 2–3 before they grew out (S1
Data). We confirmed that these cell lines were not expressing EBNA-LP from a complement-
ing virus (Fig 4B).
EBNA-LP deficient LCLs always have a memory-like cell surface phenotype
It has been reported that the IgD status of an LCL matches that of the initially infected cell pop-
ulation [39]. We therefore measured the IgD and CD27 status of LCLs from the outgrowth
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experiments of total B cells and the different B cell subsets (Figs 5A and S13). The majority of
the LCL cells established from mixed adult B cells were CD27-positive, reflecting the greater
Fig 4. EBNA-LP mutants are less efficient at transforming adult naïve B cells than memory B cells. A. Cell densities counted during outgrowth of
LCLs from different B cell subsets (indicated to the right) in two B cell donors (indicated top). The virus used is colour coded (key top centre), with
EBNA-LP mutants indicated by monochrome lines, square markers, and wild-type viruses reddish shades, diamond markers. Outgrowth data are in S1
Data. B. Western blotting for EBNA-LP (antibody 4D3) confirms the expected EBNA-LP status of the LCLs.
https://doi.org/10.1371/journal.ppat.1006890.g004
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speed of transformation of memory B cells observed in Fig 4A. Wild-type LCLs established
from naïve and unswitched memory cell subsets–expected to express IgD–were typically only
two thirds IgD-positive suggesting that this mark is only modestly preserved in LCLs. In con-
trast, over 90% of cells from memory B cell-derived LCLs were CD27-positive.
The profiles of switched and unswitched memory B cell-derived LCLs were not different
between EBNA-LP mutant and wild-type viruses, retaining the cell surface phenotype of the
parental subset. In contrast all of the LPKOw and YKO LCLs derived from naïve B cells had
memory B cell profiles, having a consistently higher CD27 status than wild-type naïve LCLs
(Fig 5B), although all LCLs have a much higher rate of CD27+ve cells than would be predicted
by their starting profile. Similarly, YKO and LPKOw LCLs from total B cells have a fewer IgD-
positive cells than wild-type LCLs (Fig 5C), suggesting a preferential transformation of mem-
ory B cells by these mutants. Overall, the low outgrowth efficiency of naïve B cells infected
with EBNA-LP mutants, and the memory-skewed profiles of EBNA-LP-deficient LCLs suggest
that EBNA-LP is important for the survival of naïve B cells, a phenotype most robustly observ-
able in cord blood LCLs.
EBNA-LP facilitates the transcription of viral but not host genes
It has been widely reported that cotransfection of EBNA-LP is able to enhance the transcrip-
tion of viral and host genes induced by EBNA2 [7,23–27]. We therefore used qPCR to analyse
host and viral transcript levels in two independent time courses across the first 30 days after
infection of CD19 isolated mixed adult B cells at an MOI of 2. Comparing the EBNA-LP
mutant viruses (LPKOi, LPKOw and YKO) with the wild-type viruses (WTHB9, WTw, E2rev,
Yrev and LPrevi) highlighted a number of differences between the groups that were consistent
between the two time courses (S3 Data). EBNA2 transcript levels were very similar across all
infections (Fig 6A), except for E2KO, which had a 10-fold higher level transcript in both the
EBNA2 and Wp assays (S3 Data). Since EBNA2 levels were transcriptionally constant between
EBNA-LP mutant and wild-type viruses (and by immunofluorescence EBNA2 protein levels
were also no different–Fig 3C), we assessed the levels of host genes that are regulated by
EBNA2. Two days post infection, known EBNA2-induced genes CD21 and HES1 [27,40] were
not induced by E2KO, but were induced normally by the EBNA-LP mutants (Fig 6B and 6C),
suggesting that EBNA-LP does not enhance the transcription of these genes by EBNA2 in the
context of EBV infection. By day 9, transcription levels were higher in the EBNA-LP mutants
than the wild-types – the opposite of what would be predicted from the transfection-based
studies – for CD21 and HES1, and also for IL7 (Fig 6D), which is not induced by EBNA2 upon
EBV infection, but does bind EBNA2 at its promoter [14], suggesting that in this context,
EBNA-LP may restrain EBNA2’s transactivation ability. The cyclin D2 gene (CCND2), was the
first EBNA2 target reported to be enhanced by EBNA-LP [7], but unlike the previous examples
is indirectly activated by EBNA2 [41]. Its transcript levels may be higher in wild-type infec-
tions than EBNA-LP mutants (Fig 6E), but this effect is inconsistent between replicates (S2
Data). Any apparent effect of EBNA-LP on CCND2 could alternatively be explained by the dif-
ferences in proliferation induced by EBNA-LP mutants and wild-type EBVs, which could
independently affect cyclin transcription. MYC activation by EBNA2 (which occurs both
directly and indirectly [41]) is clearly unaffected by the absence of EBNA-LP (Fig 6F).
Having failed to support the idea that EBNA-LP enhances the transactivation potential of
EBNA2 on host genes, we then investigated the expression of virus genes in these time courses.
In keeping with the EBNA2 enhancement hypothesis, transcription of the LMP genes (LMP1,
LMP2A and LMP2B) was delayed in EBNA-LP mutant EBV infections, reaching wild-type
expression levels in the second week post infection (Fig 7A–7C). However, EBNA3 transcripts
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were also lower in abundance from EBNA-LP mutant EBVs (Fig 7D–7F). Since EBNA3s and
EBNA2 (which was unaffected by EBNA-LP) are transcribed from the same Wp and Cp pro-
moters (see Fig 1B), we measured promoter usage, and observed an inconsistent tendency to
have slightly more Wp and less Cp transcription in EBNA-LP mutants (S14 Fig and S3 Data).
Most surprising was the failure of EBNA-LP mutants to promptly induce transcription of the
Fig 5. EBNA-LP-null LCLs only establish with a memory B cell-like phenotype. A. Flow cytometry plots show the CD27 (x-axis) and IgD status (y-
axis) of LCLs established with different viruses (top labels) in different B cell subsets (labels left) from donor B63. Numbers in the plots show the
percentage of cells in each quadrant. Naïve B cell-derived LCLs were all assayed on the same day, 39 days post infection. B & C. Graphs showing
percentage of (B) CD27+ve or (C) IgD+ve cells from LCLs (based on data from Fig 5A and S13A Fig) produced from either naïve B cells or total B cells.
Data points are shown as either EBNA-LP deficient (black square) or wild-type (orange diamond). Horizontal lines show means for each group.
https://doi.org/10.1371/journal.ppat.1006890.g005
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EBER genes, which are not EBNA2 dependent (Fig 7G and 7H). Overall, we found that muta-
tion of EBNA-LP led to a delayed transcription of all viral latency genes (other than EBNA2),
regardless of whether they were EBNA2-dependent, but did not reduce the induction of host
genes by EBNA2.
EBNA-LP facilitates EBNA2 recruitment to viral but not host promoters
EBNA-LP has reportedly been detected by chromatin immunoprecipitation (ChIP) at various
genomic loci, often in the presence of EBNA2 [42]. We have attempted to perform EBNA-LP
ChIP, but have been unable to detect any difference in EBNA-LP ChIP-qPCR signal at either
of the LMP promoters between wild-type and EBNA-LP knockout viruses in LCLs or during
primary infections (S4 Data). Since EBNA2 has been repeatedly shown to bind to and regulate
these genes, the binding of EBNA2 to both known binding sites and negative control sites (Fig
8A) was assessed across three 30 day infection time courses. The EBNA2 binding signal was
low on day 2, so differences in EBNA2 binding were only sometimes detectable (S4 Data). By
day 5 there is very little recruitment of EBNA2 to known transcription factor binding sites at
both LMP promoters on the LPKOw genome compared to WTw (Fig 8B). EBNA2 recruitment
to Cp was modestly reduced in LPKOw infections, but still showed a considerable binding sig-
nal. In contrast, recruitment of EBNA2 to host genes IL7 and HES1was more efficient after the
LPKOw infection, consistently showing elevated EBNA2 binding on days 2 and 5, but not at
later time points (Fig 8C). The reduced binding of EBNA2 to the LPKOw promoters was seen
consistently for the first 2 weeks after infection (Fig 8D). The reduced detection of viral DNA
in LPKOw ChIPs is not due to there being less viral DNA in the LPKOw cells, as the ChIP
Fig 6. Activation of EBNA2-regulated host genes is not enhanced by EBNA-LP during EBV infection. Transcript levels (measured by qPCR) were normalised
against endogenous control genes RPLP0 and ALAS1, and then expressed relative to the WTHB9 infection on day 2. Graphs A-F show levels of transcripts for the
genes named within them as a time course after infection of resting B cells, grouped as either ‘wild-type’ (comprising WTHB9, WTw, Yrev, E2rev and LPrevi) or
EBNA-LP mutants (LPKOi, LPKOw and YKO) and compared with E2KO-infected and uninfected cells on day 2 – see key bottom. Error bars show ±1 standard
deviation of the gene level for each group. Note that EBNA2 transcript level in E2KO infection was>10, so is omitted from that plot. Later time points have fewer
EBNA-LP mutant samples as some knockouts did not survive. Complete data are in S3 Data.
https://doi.org/10.1371/journal.ppat.1006890.g006
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measures recovery as a percentage of input DNA, thereby controlling for variable input DNA
levels. Thus these changes in EBNA2 binding are consistent with the lower expression of viral
genes during the same period (Fig 7), and the elevated levels of host gene transcripts on day 9
(Fig 6B–6D).
EBNA-LP facilitates host transcription factor recruitment to viral but not
host loci
EBNA2 does not bind directly to DNA, but rather it is tethered to DNA by host proteins, in
particular the transcription factor RBPJ (also called RBP-Jκ and CBF1). We therefore also
assessed RBPJ binding to the viral and host loci. RBPJ binding was slightly (but consistently)
lower in LPKOw at day 5 post infection at the LMP promoters but identical at Cp and host
locus IL7 (Fig 9A). No differences were observed on host genes at any time point (Fig 9B), or
from 9 days on for virus genes (Fig 9C), suggesting that the apparent delay in RBPJ recruit-
ment to the LPKOw genome is slighter than EBNA2. However, it is notable that the peak of
RBPJ recruitment to the viral genome (9 days) is later than the peak of EBNA2 recruitment (5
Fig 7. Viral latency genes are widely repressed in the absence of EBNA-LP. Graphs A-H show transcript levels of the viral gene named in each plot as a time course
after infection of resting B cells, grouped as either ‘wild-type’ (WTHB9, WTw, Yrev, E2rev and LPrevi) or EBNA-LP mutants (LPKOi, LPKOw and YKO)–see key
bottom right. These are compared with E2KO-infected on day 2 only, as E2KO cells did not yield sufficient RNA at later time points. Transcript levels (measured by
qPCR) are expressed relative to the level for the WTHB9 infection on day 2. Error bars show ±1 standard deviation of the transcript level for each group. Broken axes
(in A-C) are used to allow zero values to be visualised on an otherwise logarithmic axis. EBNA3 transcript levels (D-F) are shown relative to the EBNA2 transcript
level, since they share promoters, and E2KO Wp activity was very high. Later time points have fewer EBNA-LP mutant samples as some knockouts did not survive.
Complete data are in S3 Data.
https://doi.org/10.1371/journal.ppat.1006890.g007
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days) at all loci tested (Fig 9C compared to Fig 8D). This is consistent with a previous report
that shows EBNA2 arriving at loci ahead of RBPJ [14].
Recent genome-wide analyses have shown that EBNA2 and RBPJ are often located with
early B cell factor (EBF1) on the genome [42], and that the three proteins can bind together to
chromatin [14]. In addition, EBF1 binds to two RBPJ-independent sites on the EBV genome,
one near to the EBERs and the other near oriP. On day 5 post infection, EBF1 showed lower
occupancy of all of its sites on the LPKOw genome (Fig 9D), while the virus did not alter EBF1
binding to host genome loci at any time (Fig 9E). In wild-type infections, EBF1 binding
reached maximal levels at all EBNA2-bound viral sites between 5 and 9 days post infection
(Fig 9F), similar to EBNA2. Recruitment of EBF1 both to EBNA2-dependent LMP and Cp pro-
moters (Fig 9F) and to the EBNA2-independent EBER/oriP loci was delayed in LPKOw infec-
tion. It took at least two weeks to approach wild-type levels at all of the viral locations tested,
the same dynamics as EBNA2 recruitment (Fig 8D).
Overall these gene regulatory observations show a widespread failure of the LPKOw virus to
support the activation of viral genes, and the recruitment of both viral and host transcription
factors to the EBV genome, including to EBNA2-independent genes. In contrast, EBNA2-
bound host genes exhibited a transient elevation of EBNA2 recruitment that was matched by a
transient transcriptional activation. Together this suggests that EBNA-LP is required to facili-
tate the recruitment of transcriptional activators to the EBV genome, particularly between
LMP2A and oriP, but is not required for the activation of host genes by EBNA2.
Fig 8. Binding of EBNA2 to viral and host loci is influenced by EBNA-LP. ChIP analyses of EBNA2 at promoters regulated by EBNA2 in LPKOw- and WTw-
infected cells. A. Schematic representation of the EBV genome region containing latency promoters, showing positions of qPCR assays used for the ChIP. Dashed
regions of the schematic are shown shorter than in reality. B. ChIP for EBNA2 in adult B cells five days post infection with WTw (orange) and LPKOw (black). Single
letters are EBV locations per Fig 8A. EBNA2 binding sites in the host IL7 and the enhancer (En) and promoter (Pr) regions of HES1 genes are shown, with
myoglobin (MG) and MCM6 (M6) genes as negative controls. C. Time course after LPKOw and WTw infection for EBNA2 binding to IL7 as a representative host
gene locus. D. Time courses for viral promoters for LMP2A (assay A), LMP1/2B (assay B) and the RBPJK-binding site in Cp (assay R). All error bars in B-D
show ± 1 standard deviation from the mean. Complete data sets are in S4 Data.
https://doi.org/10.1371/journal.ppat.1006890.g008
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Fig 9. EBNA-LP enhances binding of host transcription factors RBPJ and EBF1 to viral but not host promoters. ChIP analyses of RBPJ (A-C) and EBF1 (D-G)
binding at viral and host promoters after infection of adult B cells with LPKOw (orange) or WTw (black). ChIP for A. RBPJ and D EBF1 five days post infection at viral
loci (single letters per Fig 8A) and genomic EBNA2/EBF-binding loci in the IL7 promoter and the HES1 enhancer (En) and promoter (Pr) regions, with myoglobin
(MG) and MCM6 (M6) genes used as negative controls. B and E. Time course after LPKOw and WTw infection for RBPJ (B) and EBF1 (E) binding to IL7 as a
representative host gene locus. C and F. Time courses for the binding of RBPJ (C) and EBF1 (F) to the EBNA2-binding regions of viral promoters for LMP2A (assay
A), LMP1 (assay B) and the RBPJK-binding site in Cp (assay R). G. Time course for EBF1 binding to EBNA2-independent EBF1 binding sites in the EBER (assay E)
and oriP (assay O) regions of the EBV genome. All error bars show ± 1 standard deviation from the mean. Full data sets are in S4 Data.
https://doi.org/10.1371/journal.ppat.1006890.g009
Genetic analysis of EBNA-LP function
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1006890 February 20, 2018 16 / 34
Discussion
Many recent advances in the understanding of EBV biology have been underpinned by the
ability to analyse gene functions in the context of EBV infection by modifying the virus
genome. The genetic analysis of EBNA-LP function represents a greater technical challenge
than other EBV genes, as EBNA-LP transcription can initiate within any one of the IR1 repeat
units. We devised a strategy using Gibson Assembly [37] to seamlessly generate an array of 6
IR1 repeat units that can generate any combination of IR1 repeat units in any order. This
could be used to assess whether the roles of the first, last or internal repeats may have different
functions, such as testing the observation that the first Wp in the genome may be more impor-
tant than the others [43].
Previous approaches to genetically assessing EBNA-LP function have been restricted to
either truncation of the protein by removal of the C terminal Y exons [28,29] or deletion of
increasing numbers of IR1 repeats, which affects Wp numbers and the sisRNAs as well as
EBNA-LP [30]. Our attempt to produce a similar Y exon knockout (YKO) virus was likely
impaired by the stop codon we recently discovered in one of the W1 exons of B95-8 IR1 [33].
The truncated EBNA-LP made by YKO is barely detectable, so it is not clear whether the
LPKO-like phenotype of YKO is because the truncated EBNA-LP is defective, or because it is
made at such a low level. It is also notable that the original WTHB9 BAC makes a much lower
amount of EBNA-LP than the repaired WTw virus (Fig 2, Fig 4 and [33]), which corresponds
to a slightly reduced outgrowth rate, most noticeably in cord B cells.
The LPKOi and LPrevi viruses–made using type IIS restriction enzyme-based strategy–have
demonstrated that apparently innocuous sequence changes in non-coding regions of IR1 can
reduce transformation. These viruses contained 4 differences from the parental IR1. Three of
these–which lie within the theoretical BWRF1 ORF–are found in a single IR1 repeat unit of
B95-8 [33], while the fourth was introduced into the small intron between exons W1 and W2.
Both of these regions are reported to give rise to stable intronic sequence RNAs (sisRNAs)
[31]. The shorter of these (sisRNA1), which derives from the W1-W2 intron, is more robustly
characterized, being detectable by Northern blot, qPCR and RNA-seq. However, it has recently
emerged that the splicing of IR1 is more complicated than previously realised: transcripts for
the anti-apoptotic Bcl2 homologue BHRF1 are spliced between W1 exons (skipping exon W2)
during the lytic cycle. Thus, it remains possible that the LPKOi and LPrevi intronic mutation
(s) may have disrupted non-EBNA splicing in IR1. However, we can conclude that the impact
of the intronic mutation is EBNA-LP-independent, as LPKOi is more defective than LPKOw,
and LPrevi is more defective than WTw. Further study is required to establish which intronic
mutation is important, and what its mechanism may be.
EBNA-LP is important for the transformation of naïve B cells
Our observations (Figs 3–5) suggest that EBNA-LP is far more important for the extended sur-
vival and proliferation of naïve B cells than memory B cells. This phenotype is clearest in cord
blood, which invariably fail to survive more than two weeks after LPKO infection. For adult
cells it is less clear. We have used CD27-negative, IgD-positive as a definition for naïve B cells
in adult blood. The EBNA-LP-deficient LCLs established from this naïve population were all
CD27+, and indeed many of the naïve B cell-derived wild-type LCLs contained substantial
CD27+ populations. This may simply reflect a technical failure of the sorting process to
remove sufficient memory B cells (although purity was over 98%) combined with a strong
selective growth advantage for memory B cells after transformation. Alternatively, it is possible
that in vitro EBV drives adult (but not cord) B cells from a naïve to a more memory-like phe-
notype. Whatever the characteristic of cord blood B cells that makes EBNA-LP essential, this
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characteristic is shared by most but perhaps not all adult CD27-/IgD+ cells. It may also be that
CD27/IgD status does not accurately reflect a cord-like naïve phenotype. Indeed, CD27 is a
somewhat flawed marker of B cell memory, since 5–25% of cord blood B cells are typically
CD27-positive [44,45] despite the neonatal immune system never having met antigen, while
CD27-/IgD- cells are reportedly a memory B cell subset [38].
Despite these uncertainties over a robust definition of naïve B cells, it is clear that EBNA-LP
is essential for the survival of a naïve or cord-like B cell subset after transformation, but not for
the survival of memory B cells. Since LPKO-infected umbilical cord B cells died two weeks
after infection of both mixed lymphocyte and CD19-isolated B cells, the difference must be
intrinsic to the B cell subsets rather than a bystander cell type. Another example of an EBV
mutant exhibiting different transformation phenotypes in different B cell subsets, is shown by
a BZLF1-knockout EBV being better able to transform germinal center B cells than memory
or naïve B cells [46]. Nevertheless, the difference between naïve and memory cells is still sur-
prising, as (at the transcriptome level) they are much more similar to each other than they are
to germinal center cells [47].
Biologically, some differences have been reported that separate the behaviour of memory
and naïve B cells. We noted a slower outgrowth of LCLs from naïve than from memory B cells,
although this was not seen in a previous study [39]. Interestingly, adult naïve B cells enter cell
cycle later than memory cells after CD40L stimulation [48], and produce fewer cells from such
cultures [49]. In cord cells the defect is more profound, with CD40 agonism barely inducing
any activation markers, whereas equivalent naïve B cell subsets from adults did respond [50].
Additionally, IgM crosslinking in cord cells failed to induce ERK1 phosphorylation, in contrast
with adult cells [50], while BCR crosslinking on adult cells induced a larger response in mem-
ory than naïve cells [51]. These observations might be relevant, since the signals from antibody
crosslinking and CD40 activation are also invoked by the LMP proteins [52]. LPKO viruses
show delayed LMP gene activation, but the inference that the deregulation of LMPs in LPKO
may be responsible for the death of naïve B cells is countered by the observation that this death
mainly manifests around 10–14 days post infection, by which time LMP transcripts in LPKO
infections are approaching wild-type levels (Fig 7).
Other phenotypic differences between naïve and memory cells may also contribute. For
instance, IL2 stimulation enhanced the production of memory cells by CD40L, but not naïve
cells [48], while 95% of cord B cells are negative for the IL2 receptor [45,50]. Naïve B cells also
have a much lower level of the anti-apoptotic BCL2 family members MCL-1 and BCL-XL (but
not BCL2 or Bim) than memory cells [53,54], which may contribute to the apoptotic pheno-
type of the LPKOw naïve cells.
Together these reports suggest that naïve and memory B cells are phenotypically different,
both in their response to pro-proliferative signaling and their resistance to apoptosis. What is
less clear is how EBNA-LP overcomes these differences in naïve cells. EBNA-LP can interact
with a complex of the tumor suppressors MDM2, p53 and the cyclin-dependent kinase inhibi-
tor p14ARF [55], which could influence both proliferation and apoptosis responses. It can also
interact with the mitochondrial protein HAX1 [56], which can be either pro- or anti-apoptotic
[57]. Alternatively, metabolic stress has been reported to be an important limitation to B cell
transformation, and has been linked to an elevated EBNA-LP:EBNA3 ratio [58]. Furthermore,
both EBNA-LP and EBNA3A have been shown to bind the prolyl-hydroxylase proteins that
influence HIF1a stability, with the suggestion that this alters the metabolic state of the infected
cells [59]. However, further study is required to understand the biology underlying the differ-
ence in transformation of naïve and memory cells, and to understand whether these differ-
ences are important for the in vivo biology and pathogenesis of EBV.
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EBNA-LP facilitates viral transcription, but does not widely enhance the
transactivation of genes by EBNA2
The function of EBNA-LP has long been linked to EBNA2 because of their co-expression
immediately after infection, and from a series of co-transfection experiments that appeared to
show an enhancement of EBNA2’s transactivation function in the presence of EBNA-LP
[7,23,24,26,27,40,60]. These studies demonstrated an ability to enhance transcription from
reporter constructs [24,60], from host genes—most notably HES1 and CCND2 (Cyclin D2)
[7,40]—and from EBV promoters repressed in the latency I transcriptional profile, including
LMP1 [23,27], Cp [60] and LMP2A [40]. Some studies have failed to replicate the regulation of
some of these genes [27], but activation of the LMP1/LMP2B bidirectional promoter has been
observed consistently. By taking a genetic approach to controlling the presence of EBNA-LP,
and by analyzing gene expression in the context of viral infection rather than transfecting iso-
lated EBV proteins, our approach differs considerably from previous studies. In doing so, we
have made substantially different observations.
First we have not observed any conclusive examples of EBNA2-regulated host genes being
enhanced by EBNA-LP. Outside transfection-based reporter assays, the only evidence of a
direct relationship between EBNA2 and EBNA-LP comes from the observation that EBNA-LP
lacking its acid-rich C-terminus (but not full-length EBNA-LP) can bind to EBNA2 [61], and
that ChIP-seq experiments imply overlap between EBNA2 and EBNA-LP binding sites on the
genome [42]. Our data are unclear as to whether (as previously reported [7]) EBNA-LP
enhances the activation of CCND2 (indirectly regulated by EBNA2 [41]), as the modest reduc-
tion in its transcription early after infection of EBNA-LP deficient cells could also be due to
their reduced proliferation. In contrast, the transient increase in EBNA2 binding to CD21, IL7
and HES1 in EBNA-LP-deficient infections (Fig 8B and 8C) followed by a transient surge in
their transcript levels (Fig 6B–6D), could be explained by a direct relationship between EBNA2
and EBNA-LP, but one where EBNA-LP restrains or modulates the transactivation of those
genes, rather than enhances it. It is also possible that the increased levels of EBNA2 at the
genes may be a consequence of the wider deregulation of the virus genome, either by modestly
increasing the EBNA2 protein levels in the cell, or freeing up EBNA2 that would normally
bind to the virus, leaving it available to bind to the host genome. Either way, these data suggest
that whatever the relationship between EBNA2 and EBNA-LP, it is not simply one of enhancer
and co-activator.
In contrast to host genes, transcription of both EBNA2-dependent (LMPs) and EBNA2-in-
dependent (EBER) genes is profoundly delayed in the absence of EBNA-LP, and there is also a
widespread delay in the recruitment of transcription factors–both viral (EBNA2) and cellular
(EBF1, and a lesser extent, RBPJ)–to the LPKOw genome. EBNA transcription is also affected,
and while EBNA2 transcripts were not affected by the loss of EBNA-LP, the reduced levels of
the EBNA3 transcripts downstream suggest that the processing of the transcripts is different in
the LPKO infection, since–like EBNA2 –they are also initiated at the Cp and Wp promoters. A
similar elevated ratio of upstream to downstream EBNAs (as a ratio of EBNA-LP to EBNA3C
protein levels) was observed in cells that have only proliferated 1–3 times after EBV infection
[36], and in cells that arrest after an initial period of proliferation [58]. This could result from
either an increase in polyadenylation after EBNA2, a change in splice site usage, or reduced
elongation of transcripts. Indeed, there is evidence that the elongation complex pTEFb is
important for transcriptional elongation from Cp, but is predicted to be less important for Wp
[62], leading to speculation that elongation of Wp transcripts is less efficient, which would lead
to lower yields of downstream EBNAs. Our data only weakly suggest a greater Wp and lesser
Cp usage. Either delayed EBNA2 recruitment to Cp or reduced EBNA1 production (which
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might be similar to the EBNA3s, as they are similarly spliced) and binding to oriP could
explain this difference.
A more profound effect was seen on the EBV latency genes between LMP2A and oriP (see
schematic in Fig 8A). Activation of this whole genome region was severely delayed in EBNA-
LP mutant infections, and this correlated with the delayed recruitment of EBF1, EBNA2
and – albeit less dramatically – RBPJK to the viral genome. The failure to induce transcription
of the EBERs demonstrates that EBNA-LP is not simply working through EBNA2, or indeed
through RNA polymerase II, as the EBERs are transcribed by RNA polymerase III, albeit regu-
lated by transcription factors more typically associated with RNA polymerase II [63]. The
region of latency genes from the LMP2A promoter to oriP represents a coordinately regulated
genomic locus. It is flanked by CTCF binding sites [64], and these loop together to form a tran-
scriptional unit. Disruption of the CTCF binding site near the LMP2A promoter can disrupt
this loop, consequently reducing LMP gene transcription and increasing repressive histone
and DNA methylation in LCLs [65]. The simplest interpretation is that EBNA-LP is important
for the proper establishment of this transcriptional unit. There is a profound delay in the
recruitment of transcription factors, but by 4 weeks post infection, the LPKO LCLs have
reached normal levels of LMP and EBER transcripts, so there does not appear to be a defect in
the maintenance of the locus once it is established in LPKO cells. EBF1 and RBPJ have been
described as a pioneer factors: transcription factors that are able to access chromatinised DNA
and establish new enhancer regions [14], so it is surprising that they would require EBNA-LP
it to efficiently access the incoming EBV genome.
Notably, this region also includes the terminal repeats, and the virus – linear in the virion –
needs to recircularize before LMP2 can be transcribed, and perhaps before this whole region is
properly regulated. In addition the terminal repeats contain a binding site for PAX5, which is
directed to the viral genome by EBER2 [66]. Two of the factors reported to bind to the EBER2/
PAX5 complex (NONO and SPFQ) have also been found to bind to EBNA-LP in a tandem
affinity mass spectrometry experiment [67], although both frequently exhibit non-specific
interactions according to the CRAPome repository [68]. Thus it is possible that EBNA-LP is
important for the efficient recircularisation of the terminal repeats, or for assembling the
EBER2/PAX5 complex on them.
Rather than just the LMP/oriP locus, EBNA-LP could be relieving the repression of the
viral genome as a whole. EBNA-LP binds to Sp100, a component of PML nuclear bodies (or
ND10). In so doing, EBNA-LP transiently disperses Sp100 from ND10 [22], and subsequently
localises to ND10 in LCLs [20]. ND10 are known inhibitors of herpesvirus early gene expres-
sion and lytic replication [21]. EBNA-LP – along with the EBV tegument protein BNRF1,
which disrupts the ND10 component DAXX – is able to complement an ICP0-null herpes sim-
plex virus, which otherwise is repressed by ND10 [69]. Thus it is reasonable to suggest that
EBNA-LP is important for preventing the suppression of latency genes of EBV by ND10 via its
interaction with Sp100, although if this is the case, it is unclear how EBNA2 transcription has
evaded this effect.
Sp100 has also been implicated in the ability of EBNA-LP to enhance EBNA2-dependent
gene transcription in transfection assays, so these phenomena may have a common origin.
However, EBNA2 coactivation has also been attributed to EBNA-LP’s ability to bind to
HDACs 4 and 5 [60], or NCOR [40]. EBNA-LP binding to NCOR and HDACs are both
reported to sequester these repressive proteins away from EBNA2-inducible genes, thereby
improving transactivation [40,60]. Any (or a combination) of these remain reasonable hypoth-
eses as to how EBNA-LP facilitates viral transcription after infection.
In summary, we have undertaken a genetic analysis of EBNA-LP function and shown that
EBNA-LP is important for B cell transformation, and essential for the transformation of naïve
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B cells, and that the role of EBNA-LP is far more complex than the previously proposed cofac-
tor for EBNA2, being particularly important for establishing the viral transcription program.
We also suggest that future analyses of EBV mutants would be better performed in distinct B
cell subsets, as it is clear that phenotypes can vary considerably according the differentiation
state of the infected B cells, and perhaps also the age of the B cell donor. The observations and
genetic manipulation strategies described herein also extend approaches to study EBNA-LP,
the EBV-sisRNAs and the wider functions of IR1 in the future.
Methods
Generation of recombinant EBVs
In order to introduce mutations into IR1, we have devised a strategy for introducing a con-
structed IR1 repeat into EBV. This entails first deleting the virus’s endogenous IR1 (to prevent
the constructed repeat from recombining with the original one) and then inserting the rebuilt
repeat. To achieve this, we used RecA-mediated recombineering as previously described [70].
The viral IR1 was deleted by joining together homology regions from the unique (non-repeti-
tive) sequences flanking IR1: The upstream region (NC_007605 positions 11413–12008),
which contains exon C2, was cloned SfiI/PciI from the B95-8 BAC (clone WTHB9); the down-
stream region (position 35239–35869) was cloned XhoI/MluI. This region was introduced by
recombineering in place of IR1. The same homology regions were used as flanks for newly
assembled IR1 repeats containing EBNA-LP mutations.
We have used two distinct methods to generate the synthetic IR1. Both approaches generate
an IR1 with 6.6 copies, which is a typical size for circulating EBV strains [32] and is the size of
IR1 in the parental EBV-BAC clone, WTHB9. In both cases, the IR1 was assembled in a
pBR322-based plasmid in DH5alpha bacteria grown at 30˚C to reduce unwanted
recombination.
The first approach used to assemble a modified IR1 adapted a strategy that used type IIs
restriction endonucleases to assemble tandem repeats [71–73]. A BamW fragment was sub-
cloned from the B95-8-BAC clone WTHB9 into a vector that contains binding sites for the type
IIb restriction endonucleases BsmBI and BtgZI. These restriction sites were engineered to both
cut at the site of the BamHI restriction site (S1B Fig). A DNA fragment (between the MfeI and
AgeI restriction sites in BamW) was synthesized, containing a point mutation of the BsmBI
restriction site in the intron between exons W1 and W2 (S1A Fig), and also containing muta-
tions that introduced STOP codons and a PvuI restriction site (Fig 1C), for making the
EBNA-LP knockout virus, LPKOi. A second synthesized fragment containing the BsmBI
mutation but not the EBNA-LP mutation was also synthesized for producing the revertant
virus, LPrevi. These fragments were cloned into the BamW repeat unit, and then both the
LPKOi and LPrevi repeat units were assembled into an array using the method described in
S1C Fig. The array was then incorporated into independent IR1 knockouts [WKO] according
to the scheme shown in Fig 1F, generating two independent LPKOi viruses, and their rever-
tants. Unintentionally, the BamW fragment used to make these viruses contained three
sequence differences from the B95-8 consensus that are present as minor variants in B95-8,
found in one of its IR1 repeat units [33].
Subsequent recombinant viruses that contained changes in IR1 were made without the
need to mutate the BsmBI restriction site in the W1-W2 intron, and using a BamW fragment
that matched the B95-8 consensus sequence. A BamW repeat unit was cloned into a
pBR322-based plasmid that contained BtgZI restriction sites that cut the BamHI sites flanking
the repeat unit. This was then modified with oligonucleotide linkers on either (or both) sides
of the BamW fragment, such that the BamW sequence was extended approximately 20bp from
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the BamHI restriction site (S9A Fig). To generate the wild-type IR1, the constructs were cut
and assembled as shown in S9A Fig, and the assembly was cloned into pKovKan and recom-
bined into the WKO.4 that had been used to produce LPKOi.2, thereby generating WTw.1 (see
Fig 1F). To generate the new EBNA-LP knockout (LPKOw) the BsmBI point mutation in the
synthesized LPKO region was reverted to the wild-type sequence by InFusion mutagenesis,
and subcloned into the new wild-type BamW fragment. The IR1 synthetic array was then
assembled in the same way as the wild-type array, and used to independently generate
LPKOw.2 and LPKOw.4 viruses by recombineering into WKO.4. E2KO, E2rev, YKO and Yrev
BACs were generated by RecA-mediated recombineering essentially as described elsewhere.
The precise sequences of the E2KO and YKO deletions are shown in Fig 1. Revertants were
made by reintroducing wild-type sequence into the knockouts by the same method (Fig 1F).
BACs were screened for integrity using EcoRI, AgeI, HindIII, NotI and BamHI restriction
digests and run on a CHEF DRII chiller pulsed field gel electrophoresis system (Bio-Rad). We
noted that the family of repeats (FR) region of oriP is smaller in WTHB9 than predicted by
sequence. This reflects a previous observation that the family of repeats region (FR) of oriP is
unstable, even in BACs, and that the FR in the p2089 BAC (of which WTHB9 is a subclone) is
300 bp smaller than the authentic sequence of B95-8 [74]. Therefore, in addition to restriction
digests, all recombinant BACs were screened by PCR, using the KA2 and KA3 primers [75]
with Q5 DNA polymerase (NEB) to ensure that the FR region was the same size in all
recombinants.
Generation of producer cell lines and virus
Recombinant EBV BAC DNA was purified from bacteria by alkaline lysis followed by cesium
chloride density gradient centrifugation. DNA was assessed by pulsed field gel electrophoresis
to ensure a predominance of intact supercoiled BAC DNA, as DNA integrity appears to influ-
ence the number and quality of producer cell lines. The BAC DNA was transfected into
293-SL cells (a culture of the HEK-293 cell line provided by Claire Shannon-Lowe; University
of Birmingham) using a peptide 6 and lipofectin transfection reagent described previously
[76]. Cells were selected with hygromycin and colonies isolated by ring cloning. Individual
hygromycin-resistant colonies were screened for GFP expression, for their ability to produce
virus. The integrity of episomes from the producer lines was assessed by recovery into bacteria
[77] and analyzed by restriction digest and pulsed field gel electrophoresis. Cell lines were only
used if at least 80% of recovered episomes were indistinguishable from the parental BAC.
To generate virus stocks, 293-EBV producer cell lines were seeded in 10 cm dishes and after
1–2 days these were transfected at approximately 25% confluency with equal quantities of
BALF4 and BZLF1-expressing plasmids: 12 μg total DNA per 10 cm plate when transfecting
with peptide6+lipofectin or 6 μg per plate using GeneJuice reagent (Merck-Millipore). Super-
natant was harvested after 5 days and filtered through a 400 nm syringe filter. Virus titer was
assayed by infecting 2x105 Raji cells in 1.5 ml with 10-fold dilutions of virus. After two days,
0.5 ml media supplemented with 20 ng/ml TPA and 5 mM sodium butyrate was added to the
Raji cells, and left overnight, to enhance GFP expression in the infected cells. Cell clumps were
dispersed by pipetting and total number of green cells per well were counted under a fluores-
cence microscope. This gave a Raji green units (rgu) titer, which was typically in the range of
0.5-10x105 rgu/ml in the cell culture supernatant.
Cell culture, isolation and analysis of immune cells and virus infections
LCLs, BL31 cells (provided by Alan Rickinson, University of Birmingham), and 293-SL cells
were grown in RPMI media supplemented with L-glutamine (Life Technologies) and 10% fetal
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calf serum. Sera were batch tested for the ability to establish 293-SL-EBV-BAC colonies after
BAC transfection, and to support outgrowth of LCLs under limiting dilution. MRC5 foreskin
fibroblasts (ATCC CCL-171), also grown in RPMI, were irradiated with 50 Gy and seeded as a
confluent monolayer to support outgrowth in some experiments.
Adult primary lymphocytes were isolated mainly from buffy-coat residues provided by
NHS Blood and Transplant. Cells concentrated from a 500 ml original blood volume were
diluted to 200 ml with PBS. Lymphocytes were isolated by layering blood-derivative on ficoll
followed by centrifugation. The isolated peripheral blood leukocytes (PBLs) were washed twice
in RPMI/1%FCS. B cells were purified from PBLs by hybridizing to anti-CD19 microbeads
(Miltenyi), using 0.5ml beads per 109 PBLs, followed by positive selection (possel program)
on an autoMACS separator (Miltenyi). Either purified B cells or PBLs were resuspended at
1-2x106 cells/ml in RPMI/15% FCS. B cell purity was measured by FACS for CD20 positivity,
and was typically over 90%.
For isolation of different adult B cell subsets, the CD19-sorted B cells were rested overnight
in a cell culture incubator, and then stained with fluorescent antibodies (from Biolegend)
against IgD (PE-CF594, clone IA6-2) and CD27 (PE-Cy7, clone M-T271). The cells were
sorted using a BD FACSAria III (BD Biosciences) into naïve and memory populations based
on IgD and CD27 status as indicated in S11 Fig, and purity was assessed by counting a few
hundred of the isolated cells on the FACSAria III (S12 Fig). Cell populations were counted and
resuspended in RPMI/15% FCS at 2x106 cells/ml for infection. CD27 and IgD status of LCLs
was assessed using the same antibodies and staining protocol, measured on an LSRFortessa
flow cytometer and analysed using FlowJo software.
Isolated PBLs or B cells were infected within a few hours of isolation/purification, by adding
virus at an MOI of 1–2 rgu/B cell, and shaking at 37˚C for 3 hours, after which cells were cen-
trifuged at 200g for 10 minutes and seeded at a density of 1-2x106 cells/ml in RPMI supple-
mented with L-glutamine and 15% FCS (batch tested for LCL outgrowth–GE healthcare or
Life Technologies) and either 50 ng/ml (for purified B cells) or 500 ng/ml (for mixed lympho-
cytes) of cyclosporin A. During outgrowth, approximately half of the media volume was
replaced every 5–7 days (cyclosporin A was omitted after two weeks), harvesting up to half of
the cells, depending on experiment.
Transformation and outgrowth assays
Blood from the umbilical cord and maternal blood was drawn from healthy full-term pregnan-
cies with written informed consent of the mother (an adult) prior to the onset of labour, over-
seen by the UK National Health Service Research Ethics Committee (approval REC 13/LP/
1712). Mononuclear cells were isolated from paired 0.5–2 ml blood samples of maternal and
cord blood by ficoll gradient centrifugation. Variations in the yields of mononuclear cells
meant that different infections were performed with different numbers of cells: two of the
three donors used equal cell numbers for maternal and cord blood infections (3.4x105 and
1x105 cells per infection). The third pair used 5x104 maternal cells, and triplicate infections of
3x105 cord cells for each virus. For most viruses (LPKOw.4; WTHB9; WTw; LPrevi; YKO.4 and
Yrev.4) 105 Raji infectious units were used for each dilution series. LPKOw.2 was used at 106
rgu per dilution series, but this higher titer showed the same transformation efficiency as
LPKOw.4.
Each infection (and an uninfected control well) was placed in a well of a 96 well plate, and
then serially diluted 2-fold ten times in RPMI/15% FCS/Cyclosporine A (100ng/ml). Media
was changed weekly and after 6 weeks the number (n) of wells containing LCLs was counted,
and number of transforming events per infection calculated as 2(n-1).
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Quantitation by cell counting was undertaken by infecting B cells (typically 5x10^5 cells–
see S1 Data and S2 Data for exceptions) at an MOI of 1 in falcon tubes for three hours, and
centrifuging and resuspending the cells in in 1ml RPMI containing 15% FCS in a 48 well plate.
Twice weekly, cells were dispersed by vigorous pipetting, and 50 ul was taken for counting.
Once per week (immediately prior to a count), 400 μl of media was removed, and replaced
with 500 μl of fresh media, to feed the cells and ensure that the volume of culture was main-
tained. For counting, 2.5 ul of solution 13 (Chemometec)–which contains Acridine Orange to
mark all cells, and DAPI to stain dead cells–was added to the 50 μl of cells. Ten μl of cells were
added to an NC-slide A8 and cells automatically counted by fluorescence on a nucleocounter
NC3000 (Chemometec). Using Nucleoview NC-3000 software (Chemometec), counted events
were gated for size to exclude debris smaller than resting cells, and counts plotted both for
total cells, and for activated cells only (defined as those with a larger Acridine Orange area
than resting B cells–S1 Data and S2 Data).
RNA analyses and quantitative reverse transcript PCR
For the time courses after infection of primary B cells, the cells were supplemented with an
equal volume of fresh media 24 hours prior to harvesting. Then, half of the culture was taken
(typically 5x105 to 2x106 cells) and RNA was extracted using RNeasy mini columns (Qiagen).
For all samples in a time course, the same quantity of RNA (~300ng) was reverse transcribed
using either Superscript III First-Strand Synthesis SuperMix for qRT-PCR (Life Technologies)
3 μl cDNA was mixed with TaqMan gene expression mastermix (Life Technologies) applied to
a custom TaqMan low density array (TLDA) card containing duplicate assays (S1 Table),
which used ALAS1, RPLP0, GNB2L1 and 18S RNA as endogenous control genes. EBV Taq-
Man assays were designed by Applied Biosystems/Life Technologies using proprietary soft-
ware, and validated using B95-8 cDNA. Sequence information is proprietary. The assay IDs in
S1 Table can be used to obtain these assays. The EBNA2 TaqMan assay extends from exon Y2
to downstream of the exon Y3 splice donor. It therefore also detects EBNA2 transcripts in the
E2KO virus, which retains these sequences. The EBNA3 TaqMan assays were designed span-
ning the exon junction between the U exon and the first exon of each EBNA3. LMP exon junc-
tions detected by LMP assays are shown in S1 Table. Additional assays (primers in S2 Table)
were conducted using Kapa qPCR SYBR kit (low ROX), and the IL7 TaqMan assay used Tak-
yon low ROX Probe 2X MasterMix dTTP (Eurogentec) and normalised against ALAS1 and
RPLP0. Quantitation of qPCR data was performed using the delta-delta-Ct method, using
DataAssist Software v3.01 (Thermo Fisher Scientific). All quantitation is expressed relative to
the level for WTHB9 on day 2 post infection. Bulk PCR of transcripts across IR1 was performed
using Q5 polymerase (NEB) and Cp-forward or Wp-forward primers with U-reverse or
Y2end-reverse primers (S2 Table).
Chromatin immunoprecipitation (ChIP)
ChIP was carried out using the Chromatin Immunoprecipitation (ChIP) Assay Kit (Millipore)
according to manufacturer’s instructions. Briefly, 2x106 infected B cells were fixed for 10 min-
utes in 1% formaldehyde and neutralised with glycine. After two PBS washes, cells were lysed
with SDS Lysis buffer on ice for 10 minutes and sonicated using the Diagenode UCD-200 Bior-
uptor for 15 minutes. Precleared chromatin, using 45μl protein A agarose beads was diluted
with ChIP dilution buffer and incubated overnight with primary antibodies against EBNA 2
(Abcam ab90543), EBF1 (Millipore AB10523), RBPJk (Abcam ab25949) or an IgG control
(Sigma). Protein A agarose beads collected the immune complexes, which were subsequently
washed in low salt, high salt, lithium chloride and twice in TE buffers. The immune complexes
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were eluted from the beads using elution buffer and left overnight at 65 degrees. After protein-
ase K treatment for 2 hours at 50 degrees, DNA was then purified using the Qiagen QIAQuick
gel extraction kit, and eluted in 120 μl water.
Chromatin was quantified by qPCR using the Kapa qPCR SYBR kit (low Rox) on a Quant-
Studio7 real time PCR machine (Applied Biosystems). Primers used for ChIP have been
described previously [78] [79] [14] [80] [62], and are listed in S3 Table. Absolute quantity (rel-
ative to input) was calculated from standard curves generated from input DNA that was seri-
ally diluted 1:4, four times. 2 μl of ChIP sample was amplified in triplicate for each qPCR assay.
Dye-dilution-based proliferation assay
Prior to infection, primary cells were resuspended at 106 cells/ml in PBS containing 5 μM Cell-
Trace Violet (Life Technologies) and incubated for 20 min at 37˚C in dark. This was then
diluted 5 times in complete B cell media and incubated for 5 min at room temperature in the
dark. Cells were washed by centrifugation and resuspended in fresh pre-warmed complete B
cell media for infection. We noted that CellTrace violet staining had a variable propensity to
kill primary B cells, so individual tubes were tested for toxicity by staining PBLs and compar-
ing B cell percentage with and without staining. Tubes exhibiting less than 50% loss of B cells
were used in experiments. For assay, cells (a volume equivalent to 106 cells in the initial infec-
tion) were harvested on ice and stained for CD20-PEVio770 (Life Technologies), and resus-
pended in PBS/1%BSA containing DRAQ7 live/dead cell stain (BioStatus). Cells were analysed
on a FACS machine (BD LSR II or LSRFortessa) and cell proliferation visualised for live
CD20+ singlet cells using FlowJo software.
DNA fragmentation assay
Approximately 106 infected B cells were resuspended in 50 μl PBS and added to 450 μl of ice
cold 70% ethanol and stored until all samples had been harvested. After least 12 hours in this
ethanol, cells were pelleted by centrifugation at 500g for 5 minutes, resuspended in 1 ml PBS,
incubated for 1 minute, pelleted, and resuspended in 100 μl PBS containing 1% triton X-100
and 1μg/ml DAPI. 30 μl of cell suspension was transferred to a NC-Slide A2 and imaged in a
nucleocounter NC-3000 (Chemometec)
Western blotting and immunofluorescence
Western blotting was performed as described previously, using RIPA lysates and run and blot-
ted onto nitrocellulose using the mini-Protein systems (Bio-Rad). Antibody clones used were:
EBNA-LP (clones JF186 [81] or 4D3 [82];gift from Yasushi Kawaguchi]); EBNA2 (Clone PE2);
EBNA3A (Ab16126, Abcam); EBNA3B (Rat monoclonal 6C9 [17]); EBNA3C (mouse mono-
clonal A10); LMP1 (monoclonal CS1-4, Dako). For immunofluorescence, cells were grown on
a 12 chamber slide (Ibidi). Cells were gently washed with PBS and then fixed with 4% parafor-
maldehyde for 15 minutes. Cells were washed twice with PBS and covered with blocking buffer
(PBS/10% FCS/100mM glycine/0.2% Triton X-100) for 30 minutes. Cells were stained with
primary antibody in 50 μl blocking buffer for one hour, washed thrice in PBS and stained with
fluorophore-conjugated secondary antibody (Cheshire Bioscience) for an hour. Chambers
were washed three times with PBS and then the chamber removed, the slide briefly dipped in
deionized water, and a coverslip mounted on the slide with Prolong Gold Antifade mount
with DAPI (Life Technologies). Slides were imaged on a Zeiss LSM5 Pascal confocal micro-
scope: 63x objective, 4x digital zoom and shown as a projection of z-stacks of 1μm sections.
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Ethics statement
Adult blood cells were purchased from UK National Blood and Transplant as waste products
of platelet isolation. As they are waste products from anonymous volunteer donors, no ethics
approval is required. Umbilical cord blood (and the maternal blood) were obtained with
written informed consent of the mother (an adult) prior to the onset of labour, under the
MatImms study, approved by the UK National Health Service Research Ethics Committee
(approval REC 13/LP/1712). Anonymized blood samples surplus to the requirements of the
MatImms study were used in this project, distributed by the Imperial College Healthcare NHS
Trust Tissue Bank (REC 12/WA/0196) and approved by the tissue bank’s Tissue Management
Committee (project R15029). Other investigators may also have received these same samples.
Supporting information
S1 Fig. Generation of viruses containing recombinant IR1 using type IIS restriction
enzymes. A. Intronic mutation introduced to remove a BsmBI restriction site in the intron to
allow this cloning method to be used. B. Method for the construction of LPKOi and LPrevi
viruses. Type IIS restriction enzyme sites used to assemble repeat arrays were designed to cut
at the same site as BamHI in a pBR322-based plasmid. The BamHI sub-fragment (BamW) was
subcloned into the BamHI site in the orientation indicated. The internal BsmBI restriction site
that was mutated to allow this construction method is outlined by a green box. Other features
of the IR1 repeat are indicated. C. Cloning strategy for the assembly of LPKOi is shown. LPrevi
assembly followed an equivalent series of cloning steps. Grey boxes indicate BamW fragments,
while white boxes indicate the SfiI/BamHI or BamHI/MluI regions at the edges of IR1 as
shown in A above. Black box within BamW represents the mutation of EBNA-LP and the
deleted BsmBI restriction site. Plasmid IDs are indicated. C and Y indicate the exons at the
flanks of the targeting region.
(PDF)
S2 Fig. Pulsed field gel analysis of recombinant EBVs. Analyses show the diagnostic digests
for the construction of: A. LPKOi and its revertand LPrevi; B. E2KO and E2rev; C. YKO and
Yrev. The size standard marker (M) is a 1:1 mixture of BstEII-lambda and Lambda mono-cut
marker (NEB). A. Recombinant LPKOi and LPrevi viruses are identical, including all contain-
ing 6.6 IR1 repeats, other than bands altered by the inserted PvuI restriction site or removal of
BsmBI. Digestion at these sites results in conversion of the IR1 band (white arrow) into the
3kb IR1 repeat unit (green arrow) and the Cp and Y bands flanking the repeat (yellow arrows).
B. Size changes in E2KO result from introduction of EcoRI and PvuI restriction sites. C. YKO
mutation produces a 140bp reduction in band size that is too small to detect in these digests,
and an introduced EcoRI restriction site that causes a more easily observed change (red
arrows). All other bands are unchanged, demonstrating the integrity of the genome outside
the intended mutations.
(PDF)
S3 Fig. Recombinant EBV validation in BL31 cells. A. To test whether the splicing of EBNA
transcripts had been affected by the changes inserted into the viruses, PCRs were conducted
between the C1 and W0 exons (upstream) and the YH exon downstream to compare the tran-
scripts produced by wild-type EBV and the LPKOi, LPrevi, and YKO EBVs. B. Western blot-
ting of EBV protein levels in BL31 cells stably infected with the various recombinant viruses. A
and B suffixes indicate independent BL31 cell lines produced from the same virus.
(PDF)
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S4 Fig. Western blot validation of EBNA2 knockouts in BL31 cells. Various western blots
for EBV proteins in cell lines infected with EBNA2 knockouts and revertants. Each lane is
identified by the virus recombinant, above the identifier of the 293 cell virus producer line,
and bottom is the BL31 cell line ID. Each lane therefore represents an independent cell line.
Note that BL31-E2KO-GK is a cell line generated using a different EBNA2-knockout EBV,
produced by Gemma Kelly and Alan Rickinson [34].
(PDF)
S5 Fig. Immunofluorescence analysis of EBNA2 and EBNA-LP expression after infection
of primary B cells 48 hours post infection. Antibodies used to label proteins are shown as
indicated. EBV-infected cells were reproducibly seen associated with pericellular foci that were
labelled by the anti-mouse secondary antibody alone. These are indicated by purple arrows.
Yellow arrows indicate an apparently nucleolar accumulation of the truncated EBNA-LP in
YKO infections. The red single channel image in YKO has been brightened to improve visuali-
sation of the faint EBNA-LP signal. Other channels use the same brightness across the experi-
ment. Note the extremely intense staining of EBNA-LP in E2KO infected cells.
(PDF)
S6 Fig. Transformation of B cells by recombinant viruses. Photographs of the accumulation
of transformed cells after infection of CD19-purified B cells by various EBV strains, taken on
days 2–20 post infection as indicated. Activated cells form clusters that then proliferate to dif-
fering extents.
(PDF)
S7 Fig. Western Blot characterisation of LPKOi, LPrevi and YKO-established LCLs. West-
ern blots of proteins from LCLs grown out from recombinant EBV infections. The virus used
for the outgrowth is indicated. Initial phase of the outgrowth of cells was either performed on
irradiated MRC5 feeder cells (F) or without feeder cells (N). The epitope in EBNA-LP recog-
nised by the JF186 antibody exists in B95-8 but is missing from most virus strains. Antibody
4D3 recognises all known EBNA-LP variants.
(PDF)
S8 Fig. Induction of proliferation by recombinant viruses. Flow cytometry plots from live
CD20-positive cells harvested either A. 3 days, B. 5 days or C. 7 days after infection of adult B
cells stained with CellTrace Violet prior to infection. Degree of dilution of the violet signal is
indicated on the x-axis, indicating number of cell divisions. Proliferation of infected cells was
measured by dilution of CellTrace violet.
(PDF)
S9 Fig. Generation of recombinant viruses containing an IR1 repeat produced by Gibson
assembly. A. Schematic representation of the Gibson assembly strategy used to generate
LPKOw and WTw. Grey boxes represent the BamW fragment and white boxes the flanks of the
repeat as described in S1 Fig. Red and orange arrows indicate the sequences either side of the
BamHI restriction site within IR1. These arrows are the homology regions whose overlap
drives the Gibson assembly of overlapping fragments as indicated in the lower part of the fig-
ure, which shows the assembly of wild-type BamW fragments into the IR1 used to generate
WTw. To generate LPKOw, the mutated W exons were cloned into each of the five plasmids
indicated, and the assembly performed in the same way. B. Pulsed field gel analysis of the
recombinant WTw and LPKOw viruses compared to the parental WTHB9. The PvuI digest
shows the presence of the knockout-specific mutation in EBNA-LP (yellow arrows), releasing
multiple copies of the 3kb IR1 repeat unit (white arrow), as compared to the parental BAC
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(WTHB9) and WTw. The other digests show the overall integrity of the rest of the virus
genome.
(PDF)
S10 Fig. Proliferation of cell lines at various time points. Flow cytometry plots from live
CD20-positive cells harvested either 4, 11 or 15 days after infection of adult B cells stained with
CellTrace violet prior to infection. Degree of dilution of the violet signal is indicated on the x-
axis, indicating number of cell divisions. Proliferation of infected cells was measured by dilu-
tion of CellTrace violet. Data for day 8 are found in Fig 3A.
(PDF)
S11 Fig. Gating strategy used to define B cell subsets. Example flow cytometry plot of mag-
netically purified B cells (CD19+ve) stained with CD27 and IgD. Coloured boxes show the
position of the gates used to separate the four subsets. IgD-/CD27- B cells (Magenta) are not a
functionally defined subset (or could be non-B cells), so have not been named.
(PDF)
S12 Fig. FACS sorter and purity plots. Plots show the IgD (y-axis) and CD27 (x-axis) status
for the pre and post-sort populations from six donors, with donor ID shown in the top of each
red box. For each donor, the top two plots show the pre-sort population (total events left;
smaller number of events right). The lower plots for each show the identity of each sorted pop-
ulation with the percentage purity shown as magenta numbers.
(PDF)
S13 Fig. EBNA-LP-null LCLs only establish with a memory B cell-like phenotype. A. Flow
cytometry plots show the CD27 (x-axis) and IgD status (y-axis) of LCLs established with differ-
ent viruses (top labels) in different B cell subsets (labels left) from donor B62. Numbers in the
plots show the percentage of cells in each quadrant, used to plot Fig 5B and 5C. Naïve B cell-
derived LCLs were all assayed on the same day, 46 days post infection. B. Similar analysis of
LCLs established from donors LC1 and LC2 (where memory-derived LCLs were from a mix-
ture of switched and unswitched memory B cells).
(PDF)
S14 Fig. QPCR analysis of Cp, Wp and total LMP2 transcription. Time course of transcript
levels based on Taqman qPCR assays spanning: A. Exon W0 to W1 to indicate activity of the
Wp promoters; B. Exon C1/2 to W1 to measure Cp promoter activity; and C. spanning exons
5 and 6 of LMP2 that measures LMP2 transcripts originating from LMP2A exon 1, LMP2B
exon 1, and terminal repeats that should constitute all LMP2 transcripts.
(PDF)
S1 Table. TLDA card Taqman qPCR assays.
(XLSX)
S2 Table. Primers used for PCR and qPCR.
(XLSX)
S3 Table. Primers used for ChIP-qPCR.
(XLSX)
S1 Data. Cell count data for LCL outgrowth from donors B62 and B63. The first tab (Expt
set up) describes the virus stocks used, their titre, the cell numbers per well used for each B cell
subset, and the amount of virus used, with resultant MOI (between 1 and 2) shown at the bot-
tom of the table. Numbers 1–6 (code number column) are the labels found in the raw data
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identifiers. B cell subset is indicated in row 5: B = total B cells; N = Naïve; UM-unswitched
memory; SM = Switched memory, defined according to IgD/CD27 status.Cell numbers per
sample (row 17) for the three subsets represents 1/6 of the total yield of cells from the sorting.
The raw data from the NC3000 is in the final tab of the workbook. Each count measured the
total live cells (gated by acridine orange area to remove debris), and also separated the cells
into two sizes—the size that matched all of the uninfected (ie smaller) cells—gate M2—and a
gate for the larger cells, that mainly appeared only after EBV infection. The second tab contains
two sets of data and plots: the left part of the tab is the total DAPI-ve cells (gate M2+M3: live
small + live large); to the right is plotted only the larger live (DAPI-ve) cells (gate M3; live large
cells only). Each set of data is plotted on linear and log scale graphs to help visualise different
aspects of the data.
(XLSX)
S2 Data. Cell count data for LCL outgrowth from cord blood B cell sample C282. The first
tab (Expt set up) describes the virus stocks used, their titre, the cell numbers per well used for
each B cell subset, and the amount of virus used, based on an MOI of 0.6, shown at the bottom
of the table. Numbers 1–6 (code number column) are the labels found in the raw data identifi-
ers. Cell numbers per sample (row 15) represents 1/7 of the total yield of cells from the mag-
netic sorting of B cells from 7 ml of cord blood. The raw data from the NC3000 is in the final
tab of the workbook. Each count measured the total live cells (gated by acridine orange area to
remove debris), and also separated the cells into two sizes—the size that matched all of the
uninfected (ie smaller) cells—gate M2—and a gate for the larger cells, that appeared only after
EBV infection. The second tab contains two sets of data and plots: the left part of the tab is the
total DAPI-ve cells (gate M2+M3: live small + live large); to the right is plotted only the larger
live (DAPI-ve) cells (gate M3; live large cells only). Each set of data is plotted on linear and log
scale graphs to help visualise different aspects of the data.
(XLSX)
S3 Data. Primary B cell infection qPCR data. The first tab contains the data from time course
2, which is shown in the figures in the main body of the paper. Time course 1 is shown in the
second tab. Differences in outgrowth speed, between the two time courses makes it hard to
meaningfully combine the data sets. Individual data measures are shown in the left set of
tables. Averages and Standard deviation by groups are in the right hand tables. Data in the
right hand table are shown normalised to endogenous control genes, and expressed relative to
the expression level for WTHB9 on day 2. For some plots on log scales, 0 values have been
changed to the lowest value on the plot (these plots are shown with broken axes in the paper
figures). These changed data are shown as red text—original data are retained in the left hand
tables.
(XLSX)
S4 Data. Chromatin immunoprecipitation (ChIP) data. These tabs contain the individual
ChIP data points and summaries used to produce Figs 8 and 9. The Expt Summary tab con-
tains a list of all ChIPs performed for EBNA2, EBF1 and RBPJ. Each B cell infection number
(column C) represents a distinct B cell donor. Time shows the time after infection that the cells
were fixed and chromatin extracted. Column E shows which ChIPs were performed on each
batch of extracted chromatin. The grid to the right shows which qPCRs were performed for
each batch of extracted chromatin. The identities of the qPCRs in row 4 match the labels in Fig
8A. The next three tabs are summaries for each of the three ChIPs, which contain the data and
plots for time courses used in the Figs 8C, 8D and 9B, 9C, 9E, 9F and 9G. The next tab—Day 5
—is the data for Figs 8B, 9A and 9D, which shows all assays on day 5. The subsequent tabs are
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the results of each independent ChIP experiment, split into tabs by ChIP Antibody (EBNA2,
RBPJ or EBF1) and time point (Day 2, 5, 9, 16, 30). A few data sets (numbers in red text in the
various tabs) were excluded from the plotted data due to technical failings with that experi-
ment or sample. These are included for full disclosure (and generally show the same trends).
(XLSX)
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